Correction: Novel anilino quinazoline-based EGFR tyrosine kinase inhibitors for treatment of non-small cell lung cancer

Lili Yang; Shanshan Liu; Jingjing Chu; Shuang Miao; Kai Wang; Qingwei Zhang; Yingyi Wang; Yadi Xiao; Lina Wu; Yang Liu; Longjian Yu; Caihong Yu; Xiang Liu; Mingxing Ke; Zhen Cheng; Xilin Sun

doi:10.1039/d2bm90028a

Correction: Novel anilino quinazoline-based EGFR tyrosine kinase inhibitors for treatment of non-small cell lung cancer

Biomater Sci. 2022 May 17;10(10):2720-2722. doi: 10.1039/d2bm90028a.

Authors

Lili Yang^{1

2}, Shanshan Liu^{1

2}, Jingjing Chu¹, Shuang Miao^{1

2}, Kai Wang^{1

2}, Qingwei Zhang^{1

2}, Yingyi Wang¹, Yadi Xiao¹, Lina Wu^{1

2}, Yang Liu^{1

2}, Longjian Yu^{1

2}, Caihong Yu^{1

2}, Xiang Liu^{1

2}, Mingxing Ke^{1

2}, Zhen Cheng³, Xilin Sun^{1

2}

Affiliations

¹ NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Molecular Imaging Research Center (MIRC), Harbin Medical University, Harbin, Heilongjiang, 150028, China.
² TOF-PET/CT/MR Center, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang, 150028, China. sunxl@ems.hrbmu.edu.cn.
³ Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University School of Medicine, Stanford, California 94305, USA. zcheng@stanford.edu.

PMID: 35403641
DOI: 10.1039/d2bm90028a

Abstract

Correction for 'Novel anilino quinazoline-based EGFR tyrosine kinase inhibitors for treatment of non-small cell lung cancer' by Lili Yang et al., Biomater. Sci., 2021, 9, 443-455. DOI: 10.1039/D0BM00293C.

Publication types

Published Erratum